# ZVRA earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ZVRA) · [Earnings tab](https://www.lopjlb.com/stock/ZVRA?tab=earnings)

Updated: 2026-08-05T05:37:59

Quarters analyzed: 8

## Cross-quarter narrative

Across the eight earnings calls from Q2 2024 to Q1 2026 Zevra’s narrative shifted from early‑stage uncertainty to a clear commercial engine centered on MIPLYFFA. The drug’s U.S. launch was confirmed in Q1 2025 and subsequently drove revenue growth, reaching $87.4 M in 2025 and supporting a 78 % YoY revenue jump in Q1 2026. European regulatory activity accelerated, with a marketing‑authorisation application submitted in Q2 2025 and under EMA review through Q1 2026. Payer reimbursement emerged as a persistent friction point, first noted as limited formulary coverage and later compounded by Medicare Part D rebate adjustments. The Celiprolol Phase III “DiSCOVER” trial has struggled with enrollment, lagging behind targets but showing incremental progress (39 → 52 enrolled). OLPRUVA’s commercial rollout faltered, prompting a scale‑back in Q3 2025. Cash resources strengthened markedly after a $150 M PRV sale, leaving the company debt‑free with >$230 M on hand. Management tone rose in Q1 2025 with a 0.6 score, then returned to neutral, reflecting mixed confidence in execution versus external risks.

## Latest CallCard · Q1

Zevra reports Q1 revenue $36.2M (+78% YoY), 170 MIPLYFFA enrollments, $236.8M cash debt-free after SDX sale; Celiprolol Phase III enrolling, EMA review ongoing.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management emphasizes disciplined execution, financial strength, strong launch traction, debt-fre

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** Zevra reports Q1 revenue $36.2M (+78% YoY), 170 MIPLYFFA enrollments, $236.8M cash debt-free after SDX sale; Celiprolol Phase III enrolling, EMA review ongoing.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management emphasizes disciplined execution, financial strength, strong launch traction, debt-fre
- **2025 Q4:** Zevra reports $106.5M 2025 revenue driven by MIPLYFFA ($87.4M), with 52 enrollment forms in 2025 and growing newly diagnosed patients; EU MAA under review, Celiprolol enrollment at 52/150, cash $238.9M, no 2026 revenue guidance.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management emphasized strong 
- **2025 Q3:** Zevra reported $26.1M Q3 revenue driven by MIPLYFFA, highlighted strong U.S. uptake, European MAA under review, scaled back OLPRUVA marketing, and noted a $1.2M Medicare Part D rebate true‑up affecting net sales.
- **2025 Q2:** Zevra Q2: $25.9M revenue, PRV sale $150M, MIPLYFFA launch 129 scripts (7 in Q2), EU MAA submitted, OLPRUVA slow, celiprolol 39/150 enrolled.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights robust demand, strong MIPLYFFA launch penetration (>1/3 diagnosed US patients), 26% QoQ revenue
- **2025 Q1:** Zevra reports strong Q1 launch of MIPLYFFA with robust enrollment and cash strength, while noting payer coverage limits and slower Celiprolol trial enrollment.
- **2024 Q4:** —
- **2024 Q3:** Zevra launched MIPLYFFA for NPC with 90 enrollments by Oct 31, exceeding expectations; OLPRUVA underperforming with 3 Q3 enrollments; exploring strategic alternatives for KP1077 in IH; restructuring pipeline and closing facilities. PRV monetization planned for nondilutive capital. Europe submission 
- **2024 Q2:** Zevra reports Q2 progress: arimoclomol AdCom favorable

## Theme arcs

- **MIPLYFFA commercial traction** (improving): US launch completed and revenue contribution grew each quarter
- **European regulatory progress** (new): MAA submitted in Q2 2025, under EMA review through Q1 2026
- **Payer reimbursement challenges** (deteriorating): Limited formulary coverage noted in 2025 and Medicare Part D rebate impact in Q3 2025
- **Celiprolol trial enrollment** (deteriorating): Enrollment behind target but slowly increasing (39→52)
- **OLPRUVA commercial performance** (deteriorating): Initial strategy in Q1 2025, scaled back and at risk by Q3 2025
- **Financial strength/cash position** (improving): PRV sale added $150 M; cash >$230 M and debt‑free by Q1 2026

## Fear persistence

- **Payer coverage/reimbursement** [recurring]: Limited formulary coverage in 2025 and Medicare Part D rebate impact in Q3 2025
- **Trial enrollment pace** [recurring]: Celiprolol/DiSCOVER enrollment behind target across multiple quarters
- **Regulatory timing** [recurring]: Uncertainty around EMA review of European MAA
- **Competitive landscape** [resolved]: Only mentioned in Q1 2025, no later references
- **Rare disease market size** [resolved]: Discussed in Q1 2025, absent thereafter
- **Revenue recognition/gross‑to‑net adjustments** [new]: Raised as a risk in Q3 2025 due to rebate redesign
- **Product adoption (OLPRUVA)** [new]: Scale‑back and at‑risk status highlighted in Q3 2025

## Guidance path

2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:maintained → 2025 Q4:vague → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/ZVRA`